Amgen Licenses Micromet Technology | Chemical & Engineering News
Volume 89 Issue 29 | p. 18 | Concentrates
Issue Date: July 18, 2011

Amgen Licenses Micromet Technology

Department: Business
Keywords: cancer, antibodies, drug discovery

Amgen will pay Micromet $14 million up front to apply the Rockville, Md.-based biotech firm’s BiTE antibody technology against three solid-tumor targets. Amgen has the right to develop BiTE antibodies against two of the targets. It will cover all the program’s R&D costs, which the companies say could run up to $35 million. Micromet’s BiTE antibodies bind T cells to tumor cells, prompting cell death as well as the proliferation of more T cells at the tumor site.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment